Serum immunoglobulins and biomarkers of dementia: a population-based study.
Biomarkers
Dementia
Immunoglobulins
Neuroimaging
Population-based
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
07 11 2023
07 11 2023
Historique:
received:
20
09
2022
accepted:
15
10
2023
medline:
9
11
2023
pubmed:
8
11
2023
entrez:
8
11
2023
Statut:
epublish
Résumé
Inflammation plays a key role in the development of dementia, but its link to early biomarkers, particularly those in plasma or neuroimaging, remains elusive. This study aimed to investigate the association between serum immunoglobulins and biomarkers of dementia. Between 1997 and 2009, serum immunoglobulins (IgA, IgG and IgM) were measured in dementia-free participants of the population-based Rotterdam Study. A random subset of participants had assessment of biomarkers in plasma (total tau (t-tau), neurofilament light chain (NfL), amyloid-β40 (Aβ-40), amyloid-β42 (Aβ-42), while another subset of participants underwent neuroimaging to quantify brain volume, white matter structural integrity and markers of cerebral small vessel disease. Linear regression models were constructed to determine cross-sectional associations between IgA, IgG, IgM and biomarkers of dementia, with adjustment for potential confounders. Multiple testing correction was applied using the false discovery rate. As a sensitivity analysis, we re-ran the models for participants within the reference range of immunoglobulins, excluding those using immunomodulating drugs, and conducted a stratified analysis by APOE-ε4 carriership and sex. Of 8,768 participants with serum immunoglobulins, 3,455 participants (65.8 years [interquartile range (IQR): 61.5-72.0], 57.2% female) had plasma biomarkers available and 3,139 participants (57.4 years [IQR: 52.7-60.7], 54.4% female) had neuroimaging data. Overall, no associations between serum immunoglobulins and biomarkers of dementia remained significant after correction for multiple testing. However, several suggestive associations were noted: higher serum IgA levels concurred with lower plasma levels of Aβ-42 (standardized adjusted mean difference: -0.015 [95% confidence interval (CI): -0.029--0.002], p = 2.8 × 10 While associations between serum immunoglobulins and early markers of dementia could not be established in this population-based sample, it may be valuable to consider factors such as APOE-ε4 allele carriership and sex in future investigations.
Sections du résumé
BACKGROUND
Inflammation plays a key role in the development of dementia, but its link to early biomarkers, particularly those in plasma or neuroimaging, remains elusive. This study aimed to investigate the association between serum immunoglobulins and biomarkers of dementia.
METHODS
Between 1997 and 2009, serum immunoglobulins (IgA, IgG and IgM) were measured in dementia-free participants of the population-based Rotterdam Study. A random subset of participants had assessment of biomarkers in plasma (total tau (t-tau), neurofilament light chain (NfL), amyloid-β40 (Aβ-40), amyloid-β42 (Aβ-42), while another subset of participants underwent neuroimaging to quantify brain volume, white matter structural integrity and markers of cerebral small vessel disease. Linear regression models were constructed to determine cross-sectional associations between IgA, IgG, IgM and biomarkers of dementia, with adjustment for potential confounders. Multiple testing correction was applied using the false discovery rate. As a sensitivity analysis, we re-ran the models for participants within the reference range of immunoglobulins, excluding those using immunomodulating drugs, and conducted a stratified analysis by APOE-ε4 carriership and sex.
RESULTS
Of 8,768 participants with serum immunoglobulins, 3,455 participants (65.8 years [interquartile range (IQR): 61.5-72.0], 57.2% female) had plasma biomarkers available and 3,139 participants (57.4 years [IQR: 52.7-60.7], 54.4% female) had neuroimaging data. Overall, no associations between serum immunoglobulins and biomarkers of dementia remained significant after correction for multiple testing. However, several suggestive associations were noted: higher serum IgA levels concurred with lower plasma levels of Aβ-42 (standardized adjusted mean difference: -0.015 [95% confidence interval (CI): -0.029--0.002], p = 2.8 × 10
CONCLUSIONS
While associations between serum immunoglobulins and early markers of dementia could not be established in this population-based sample, it may be valuable to consider factors such as APOE-ε4 allele carriership and sex in future investigations.
Identifiants
pubmed: 37936180
doi: 10.1186/s13195-023-01333-3
pii: 10.1186/s13195-023-01333-3
pmc: PMC10629143
doi:
Substances chimiques
Amyloid beta-Peptides
0
tau Proteins
0
Amyloid
0
Biomarkers
0
Apolipoproteins E
0
Immunoglobulin A
0
Immunoglobulin G
0
Immunoglobulin M
0
Apolipoprotein E4
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
194Subventions
Organisme : Takeda
ID : IIR-NLD-002671
Informations de copyright
© 2023. The Author(s).
Références
Nat Rev Neurosci. 2015 Jun;16(6):358-72
pubmed: 25991443
Immunol Rev. 2018 Jul;284(1):132-147
pubmed: 29944755
Neurol Ther. 2019 Dec;8(Suppl 2):73-82
pubmed: 31833025
J Alzheimers Dis. 2016 Dec 6;55(3):899-903
pubmed: 27767997
Alzheimer Dis Assoc Disord. 1990 Summer;4(2):79-86
pubmed: 2357340
N Engl J Med. 2012 Jul 5;367(1):20-9
pubmed: 22762315
Neurology. 2018 Apr 17;90(16):e1386-e1394
pubmed: 29549218
DNA Cell Biol. 2014 Dec;33(12):823-9
pubmed: 25188736
Eur J Epidemiol. 2015 Dec;30(12):1299-315
pubmed: 26650042
J Neuroinflammation. 2019 Mar 30;16(1):68
pubmed: 30927918
Alzheimers Dement. 2015 Mar;11(3):321-30
pubmed: 25217294
Cell Mol Neurobiol. 2019 Oct;39(7):1061-1065
pubmed: 31203531
J Alzheimers Dis. 2017;58(4):1303-1313
pubmed: 28582858
Acta Neuropathol. 2018 Dec;136(6):887-900
pubmed: 30334074
J Neuroimmune Pharmacol. 2020 Dec;15(4):852-862
pubmed: 32090272
J Clin Immunol. 2014 Jul;34 Suppl 1:S74-9
pubmed: 24760112
J Neurol. 2023 Jan;270(1):423-432
pubmed: 36123443
Neuron. 2015 Oct 21;88(2):237-9
pubmed: 26494271
J Neurol Sci. 2003 May 15;209(1-2):93-9
pubmed: 12686409
Dialogues Clin Neurosci. 2009;11(2):111-28
pubmed: 19585947
Front Immunol. 2021 Apr 07;12:664526
pubmed: 33897714
Nat Rev Immunol. 2018 Dec;18(12):759-772
pubmed: 30140051
Alzheimers Res Ther. 2018 Aug 16;10(1):81
pubmed: 30115117
Neurology. 2016 Sep 27;87(13):1329-36
pubmed: 27581216
Lancet Neurol. 2013 Feb;12(2):207-16
pubmed: 23332364
Neurosci Lett. 2006 Dec 20;410(2):90-3
pubmed: 17095156
Anal Chem. 2011 Mar 15;83(6):2279-85
pubmed: 21344864
Alzheimers Res Ther. 2018 Jan 29;10(1):10
pubmed: 29378642
J Clin Immunol. 2021 Nov;41(8):1902-1914
pubmed: 34505230
Hum Brain Mapp. 2018 Jun;39(6):2500-2513
pubmed: 29468773
Brain. 2020 Apr 1;143(4):1220-1232
pubmed: 32206776
J Biol Chem. 2003 Dec 5;278(49):48529-33
pubmed: 14507923
Dement Geriatr Cogn Disord. 2004;18(2):165-71
pubmed: 15211072
J Neurol. 2021 Aug;268(8):2769-2779
pubmed: 32306172
Ann Clin Transl Neurol. 2014 Oct;1(10):822-32
pubmed: 25493273
Lancet Neurol. 2016 Apr;15(5):455-532
pubmed: 26987701
Ethn Dis. 2011 Spring;21(2):142-9
pubmed: 21749016
Front Aging Neurosci. 2019 Feb 11;11:14
pubmed: 30804776
Arch Neurol. 2004 May;61(5):668-72
pubmed: 15148142
Acta Neuropathol. 1982;57(2-3):239-42
pubmed: 6812382
Neuroimage. 2009 May 1;45(4):1151-61
pubmed: 19344687
Eur J Epidemiol. 2020 May;35(5):483-517
pubmed: 32367290